Mon panier

Integrin alpha V beta 1

Integrin alpha V beta 1 Informations sur la molécule

Nom anglaisIntegrin alpha-V/beta-1Nombre de médicaments commercialisés0
Nombre de médicaments cliniques5Alias de la cible
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisIntegrin alpha-V/beta-1
Alias de la cible
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques5
Phase de R&D la plus avancéePhase 2 Clinical

Integrin alpha V beta 1 Liste de produits

  • Attribut

    Protein (6)

  • Bibliothèque de produits

    En ligne (6)

  • Espèces

    Human (3)Cynomolgus (1)Rat (1)Mouse (1)

  • Étiquette

    His Tag (3)His Tag & Avi Tag (1)Tag Free (1)Flag Tag (1)

  • Marqueur

    Unconjugated (5)Biotin-labeled (1)

Integrin alpha V beta 1Contexte de la molécule

Integrin alpha V beta 1 (αVβ1) is a widely expressed adhesion receptor formed by the non-covalent association of the αV and β1 (CD29) subunits. Its activity is regulated by a conformational shift from a folded, low-affinity state to an extended, high-affinity state, a process triggered by divalent cations and intracellular signaling. As a canonical RGD-binding integrin, it interacts with ligands including vitronectin, fibronectin, and osteopontin. This interaction is central to its role in mediating cell migration, where its modest binding affinity enables the cyclic attachment and detachment necessary for cell movement. Furthermore, αVβ1 is implicated in cellular differentiation and is co-opted by pathogens, such as foot-and-mouth disease virus, for host cell entry.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
IDL-2965IDL-2965Phase 2 ClinicalIndalo Therapeutics IncIdiopathic Pulmonary Fibrosis; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
BexotegrastPLN-74809Phase 2 ClinicalPliant Therapeutics IncCholangitis, Sclerosing; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Respiratory Distress Syndrome, Adult
Details
PLN-1474PLN-1474Phase 1 ClinicalPliant Therapeutics IncLiver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
PLN-101095PLN-101095Phase 1 ClinicalPliant Therapeutics IncSolid tumours
Details
Cu-64-LLP2ACu-64-LLP2A; 64Cu-LLP2APhase 1 ClinicalUniversity Of PittsburghAnemia, Sickle Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma; Waldenstrom Macroglobulinemia
Details

Avis sur les produits

  • Informations sur la molécule
  • Liste de produits
  • Avis sur les produits
  • Informations sur les médicaments cliniques